J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 9, Number 3, March 2017, pages 207-212

The Effectiveness of a Liver Disease Education Class for Providing Information to Patients and Their Families

Figure 1. Relationship between knowledge degree just before the lecture and times of attendance to classroom for liver diseases. Because comparison (Kurskal-Wallis) of multi-groups revealed significant difference in (a) (P < 0.0001), (b) (P = 0.0388), (c) (P = 0.0021), and (d) (P < 0.0001), Mann-Whitney test was conducted. P values by Mann-Whitney test are indicated. (a) Prophylaxis of hepatic cancer. (b) Treatment of hepatic cancer. (c) Significance of iron restrictions in the C type liver disease. (d) Significance of BCAA.

**Table 1.** Knowledge Degree of Patients and Family and the Times of Experience to Attend Classrooms
Tips of information/times of experience of classroom	Patients	Family	P value
Comparisons were performed using Mann-Whitney test. Data were shown as mean ± SD. HC: hepatic cancer; BCAA: branched-chain amino acid.
Prophylaxis of HC
0	1.00 ± 0.82	0.67 ± 0.49	0.3034
1 - 2	1.36 ± 0.78	1.30 ± 0.48	0.7027
≥ 3	2.30 ± 0.48	1.67 ± 0.57	0.0958
Treatment of HC
0	1.33 ± 1.16	0.75 ± 0.71	0.3305
1 - 2	1.27 ± 0.96	0.83 ± 0.41	0.2824
≥ 3	2.00 ± 0.63	2.00	> 0.99
Iron restriction
0	1.00 ± 0.89	0 ± 0	0.0258
1 - 2	1.17 ± 0.39	1.00 ± 0	0.4631
≥ 3	2.75 ± 0.50	1.50 ± 0.71	0.0801
Effects of BCAA
0	0.60 ± 0.70	0.17 ± 0.58	0.0521
1 - 2	0.85 ± 0.66	0.56 ± 0.73	0.2278
≥ 3	2.30 ± 0.68	1.33 ± 0.58	0.0564

Table 1. Knowledge Degree of Patients and Family and the Times of Experience to Attend Classrooms

Tips of information/times of experience of classroom

Patients

Family

P value

Comparisons were performed using Mann-Whitney test. Data were shown as mean ± SD. HC: hepatic cancer; BCAA: branched-chain amino acid.

Prophylaxis of HC

1.00 ± 0.82

0.67 ± 0.49

0.3034

1 - 2

1.36 ± 0.78

1.30 ± 0.48

0.7027

≥ 3

2.30 ± 0.48

1.67 ± 0.57

0.0958

Treatment of HC

1.33 ± 1.16

0.75 ± 0.71

0.3305

1 - 2

1.27 ± 0.96

0.83 ± 0.41

0.2824

≥ 3

2.00 ± 0.63

2.00

> 0.99

Iron restriction

1.00 ± 0.89

0 ± 0

0.0258

1 - 2

1.17 ± 0.39

1.00 ± 0

0.4631

≥ 3

2.75 ± 0.50

1.50 ± 0.71

0.0801

Effects of BCAA

0.60 ± 0.70

0.17 ± 0.58

0.0521

1 - 2

0.85 ± 0.66

0.56 ± 0.73

0.2278

≥ 3

2.30 ± 0.68

1.33 ± 0.58

0.0564

**Table 2.** Changes of Knowledge Degree of Participants by Attending Classrooms
Tips of information/times of experience of classroom	Patients	Family	P value
Comparisons were performed using Wilcoxon test. Data were shown as mean ± SD. HC: hepatic cancer; BCAA: branched-chain amino acid; ND: not determined because small number of subjects.
Prophylaxis of HC
0	0.76 ± 0.63	2.05 ± 0.38	< 0.0001
1 - 2	1.34 ± 0.71	2.09 ± 0.45	< 0.0001
≥ 3	2.07 ± 0.62	2.54 ± 0.52	0.0956
Treatment of HC
0	0.91 ± 0.83	2.00 ± 0.0	0.0339
1 - 2	1.14 ± 0.85	1.91 ± 0.54	0.0114
≥ 3	ND	ND	ND
Iron restriction
0	0.54 ± 0.78	2.31 ± 0.63	0.0012
1 - 2	1.13 ± 0.35	2.54 ± 0.52	0.0017
≥ 3	2.14 ± 0.90	3.00 ± 0.0	0.0633
Effects of BCAA
0	0.32 ± 0.63	1.86 ± 0.56	< 0.0001
1 - 2	0.78 ± 0.68	1.85 ± 0.71	< 0.0001
≥ 3	2.00 ± 0.78	2.46 ± 0.69	0.0588

Table 2. Changes of Knowledge Degree of Participants by Attending Classrooms

Tips of information/times of experience of classroom

Patients

Family

P value

Comparisons were performed using Wilcoxon test. Data were shown as mean ± SD. HC: hepatic cancer; BCAA: branched-chain amino acid; ND: not determined because small number of subjects.

Prophylaxis of HC

0.76 ± 0.63

2.05 ± 0.38

< 0.0001

1 - 2

1.34 ± 0.71

2.09 ± 0.45

< 0.0001

≥ 3

2.07 ± 0.62

2.54 ± 0.52

0.0956

Treatment of HC

0.91 ± 0.83

2.00 ± 0.0

0.0339

1 - 2

1.14 ± 0.85

1.91 ± 0.54

0.0114

≥ 3

Iron restriction

0.54 ± 0.78

2.31 ± 0.63

0.0012

1 - 2

1.13 ± 0.35

2.54 ± 0.52

0.0017

≥ 3

2.14 ± 0.90

3.00 ± 0.0

0.0633

Effects of BCAA

0.32 ± 0.63

1.86 ± 0.56

< 0.0001

1 - 2

0.78 ± 0.68

1.85 ± 0.71

< 0.0001

≥ 3

2.00 ± 0.78

2.46 ± 0.69

0.0588